
InfuSystem Hlds (INFU) Stock Forecast & Price Target
InfuSystem Hlds (INFU) Analyst Ratings
Bulls say
InfuSystems Holdings Inc. has demonstrated a solid upward trajectory, highlighted by record quarterly revenues from its core oncology business and a new contract with a significant hospital system poised to enhance patient volumes in the near term. The company's gross profit margin experienced a substantial increase of 370 basis points to 55.2%, attributed to optimized revenue mix and controlled pump disposal costs, indicating effective cost management and operational efficiencies. Furthermore, year-to-date net operating cash flow has risen to $17.3 million, a significant 38% increase, showcasing higher earnings and improved working capital management, with expectations of continued margin expansion as strategic initiatives are implemented over the coming months.
Bears say
InfuSystems Holdings has reported declining gross margins, particularly in its Device Solutions segment, while also facing rising operational costs. Economic uncertainties have contributed to a decrease in demand and sales volumes due to customer destocking, further exerting pressure on the company's margins. These challenges are projected to negatively impact revenue estimates for fiscal year 2026, which remain flat compared to fiscal year 2025, indicating potential difficulties in revenue growth and profitability.
This aggregate rating is based on analysts' research of InfuSystem Hlds and is not a guaranteed prediction by Public.com or investment advice.
InfuSystem Hlds (INFU) Analyst Forecast & Price Prediction
Start investing in InfuSystem Hlds (INFU)
Order type
Buy in
Order amount
Est. shares
0 shares